Key Highlights
- CVS delivered adjusted earnings of $2.57 per share, surpassing analyst expectations of $2.18, continuing a streak of five consecutive beats
- Quarterly revenue reached $100.4 billion, significantly exceeding Wall Street’s $95 billion projection
- The medical benefit ratio at Aetna decreased to 84.6%, an improvement from last year’s 87.3%
- The company increased its 2026 adjusted EPS forecast to a range of $7.30–$7.50 from the previous $7.00–$7.20
- Shares of CVS rose 4.9% during premarket hours on the back of these results
CVS Health shares surged 4.9% before Wednesday’s opening bell following an impressive first-quarter performance and an upward revision to its annual outlook.
The healthcare giant reported adjusted earnings per share of $2.57, comfortably exceeding the consensus estimate of $2.18 among analysts. Total revenue of $100.4 billion similarly outperformed expectations, topping the anticipated $95 billion figure.
This performance represents the company’s fifth consecutive quarter of beating projections. CVS has maintained conservative guidance throughout its ongoing transformation efforts following a challenging 2024.
Management boosted the company’s full-year 2026 adjusted earnings per share guidance to between $7.30 and $7.50, raised from the prior range of $7.00 to $7.20. Additionally, CVS elevated its operating cash flow projection to a minimum of $9.5 billion, up from the previous floor of $9 billion.
Prior to Wednesday’s session, the stock had posted modest gains of only 1.7% for the year, underperforming the S&P 500’s 6% advance.
Aetna Shows Significant Medical Cost Efficiency
The most impressive metric came from the Aetna insurance division, where the medical benefit ratio registered at 84.6%, substantially below analyst projections of 87.58% and marking a notable decline from the prior year’s 87.3%.
This ratio indicates the proportion of premium dollars allocated to actual healthcare expenses. Lower figures reflect stronger profitability for insurers. CFO Brian Newman attributed the enhancement to superior forecasting capabilities and tighter expense management.
Both UnitedHealth and Humana similarly exceeded projections on this measure during the first quarter, suggesting widespread operational gains among Medicare Advantage providers.
Federal regulators announced in April that 2027 reimbursement rates for Medicare Advantage plans would increase by an average of 2.48%. However, Newman noted this adjustment remains below anticipated medical cost inflation for the coming year, potentially requiring CVS to modify pricing structures or plan benefits.
Pharmacy Services Grow While Retail Operations Face Headwinds
The health services division, encompassing the Caremark pharmacy benefit management business, generated revenue growth of 11% to reach $48.2 billion. Operating profit totaled $1.34 billion, meeting analyst forecasts.
Newman pointed to an enhanced pharmaceutical product mix as a driver behind Caremark’s stronger performance. Leerink analyst Michael Cherny had previously identified achieving $1.3 billion in adjusted operating income for this segment as critical for rebuilding investor trust.
Pharmacy benefit managers continue facing scrutiny from policymakers and regulatory agencies regarding drug pricing mechanisms. CVS has a pending Federal Trade Commission settlement related to accusations that its PBM artificially elevated insulin costs, charges the company contests.
The company is also challenging Tennessee legislation that would prohibit PBMs from operating retail pharmacies within state borders. The measure has cleared both legislative chambers and awaits gubernatorial consideration.
CVS’s retail pharmacy operations reported a 5% revenue increase in 2025 following the acquisition of locations from Rite Aid, which brought 9 million additional customers into its system. However, operating income for this division declined 8.8% compared to the same quarter last year.
The company attributed the pharmacy segment’s profit pressure to regulatory modifications affecting certain medication pricing, diminished seasonal illness activity, and weather-related disruptions — including temporary closures due to winter storms.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
